Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06660654 · ClinicalTrials.gov registry record · Phase 2
A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)
A Phase 2 study of Advanced Solid Tumor and Metastatic Solid Tumors, sponsored by Daiichi Sankyo.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 20
- Study locations
NCT06660654: Recruiting Phase 2 study of Advanced Solid Tumor and Metastatic Solid Tumors, sponsored by Daiichi Sankyo.
NCT06660654 is a Phase 2 study of Advanced Solid Tumor and Metastatic Solid Tumors that is actively recruiting participants, run by Daiichi Sankyo. The registered enrollment target is 200 participants, roughly in line with the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target. The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06660654, a Phase 2 study of Advanced Solid Tumor and Metastatic Solid Tumors, is actively recruiting participants, sponsored by Daiichi Sankyo.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 20
- Study locations
Study Summary
This pan-tumor trial is designed as a signal-seeking trial to assess efficacy and safety of raludotatug deruxtecan (R-DXd) monotherapy in locally advanced or metastatic solid tumors with various cadherin-6 (CDH6) expression levels, including gynecological cancers (endometrial cancer, cervical cancer, and non-high-grade serous ovarian cancer) and genitourinary cancers (urothelial cancer and clear cell renal cell carcinoma \[ccRCC\]).
Primary Outcome
Objective response rate (ORR) is defined as the proportion of participants with a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST version 1.1 criteria.
Conditions Studied
Interventions
- DRUG Raludotatug deruxtecan
Study Locations (20)
Other
- UZ Leuven Gynaec onco - Leuven
- ZAS Sint-Augustinus - Wilrijk
- Hunan Cancer Hospital - Changsha
- Shanghai Cancer center - Shanghai
- Herlev og Gentofte Hosp - Copenhagen
- François Baclesse Center - Caen
- Centre Georges-François Leclerc - Dijon
- Centre Oscar Lambret - Lille
- Centre Leon Berard - Lyon
- Grp Hsp Diac Croix Saint Simon - Paris
- Cario - Centre Armoricain de Radiothérapie, Imagerie Médicale Et Oncologie - Plérin
- Ico - Site René Gauducheau - Saint-Herblain
New York
- Women's Cancer Care Associates - Albany
- Memorial Sloan-Kettering Cancer Center - New York
- Clinical Research Alliance - Westbury
Georgia
- Northside Hospital - Marietta
Michigan
- University of Michigan Comprehensive Cancer Center Michigan Medicine - Ann Arbor
New Jersey
- Astera Cancer Care - East Brunswick
Tennessee
- West Cancer Center and Research Institute - Germantown
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-01-06 |
| Est. Completion | 2027-09-30 |
| Phase | Phase 2 |
What NCT06660654 shows while recruiting
NCT06660654 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target.
The record links to 2 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which Raludotatug deruxtecan is the first listed.
NCT06660654 names 20 study sites across 7 states, led by Other, New York, Georgia.
Frequently Asked Questions
What is clinical trial NCT06660654 about?
NCT06660654 is a clinical study titled "A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)". This pan-tumor trial is designed as a signal-seeking trial to assess efficacy and safety of raludotatug deruxtecan (R-DXd) monotherapy in locally advanced or metastatic solid tumors with various cadherin-6 (CDH6) expression levels, including gynecological cancers (endometrial cancer, cervical cancer...
What is the current status of trial NCT06660654?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2025-01-06. Estimated completion is 2027-09-30.
What conditions does trial NCT06660654 study?
This clinical trial studies the following conditions: Advanced Solid Tumor, Metastatic Solid Tumors.
What interventions are being tested in trial NCT06660654?
The interventions under investigation include: Raludotatug deruxtecan (DRUG).
Who is sponsoring clinical trial NCT06660654?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06660654 being conducted?
This trial has 20 study locations across Georgia, Michigan, New Jersey, New York, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06660654's enrollment target sits among peer trials
200 66th of 189 higher than 121 of 189 other Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
RECRUITING · Phase 2
-
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 2
-
Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations
ACTIVE NOT RECRUITING · Phase 2
-
Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors
COMPLETED · Phase 2
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI